Actinver Wealth Management Inc. bought a new position in shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 28,460 shares of the company’s stock, valued at approximately $2,409,000. Actinver Wealth Management Inc. owned 0.07% of Taro Pharmaceutical Industries at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in TARO. WESPAC Advisors SoCal LLC acquired a new position in shares of Taro Pharmaceutical Industries during the fourth quarter worth $53,000. Quantamental Technologies LLC bought a new stake in Taro Pharmaceutical Industries in the fourth quarter valued at $110,000. Two Sigma Advisers LP increased its stake in Taro Pharmaceutical Industries by 12.5% in the fourth quarter. Two Sigma Advisers LP now owns 2,700 shares of the company’s stock valued at $229,000 after purchasing an additional 300 shares in the last quarter. Jane Street Group LLC bought a new stake in Taro Pharmaceutical Industries in the fourth quarter valued at $239,000. Finally, GSA Capital Partners LLP bought a new stake in Taro Pharmaceutical Industries in the third quarter valued at $315,000. 10.07% of the stock is currently owned by institutional investors.
TARO has been the subject of several recent research reports. TheStreet raised shares of Taro Pharmaceutical Industries from a “c” rating to a “b-” rating in a research report on Friday, February 15th. Zacks Investment Research cut shares of Taro Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Wednesday, April 3rd. Finally, ValuEngine upgraded shares of Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating in a research note on Thursday, January 10th.
Taro Pharmaceutical Industries (NYSE:TARO) last posted its earnings results on Wednesday, February 6th. The company reported $2.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.95 by $0.45. The business had revenue of $176.38 million for the quarter, compared to analyst estimates of $174.70 million. Taro Pharmaceutical Industries had a net margin of 46.55% and a return on equity of 14.27%. On average, sell-side analysts anticipate that Taro Pharmaceutical Industries Ltd. will post 7.97 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/04/24/actinver-wealth-management-inc-buys-shares-of-28460-taro-pharmaceutical-industries-ltd-taro.html.
Taro Pharmaceutical Industries Profile
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
Featured Article: Trading Stocks – What are percentage gainers?
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.